

TABLE OF CONTENTS

TABLE OF AUTHORITIES.ii

INTRODUCTION 1

I. INTEREST AND EXPERTISE OF THE FEDERAL TRADE COMMISSION . . 1

II. BACKGROUND 4

 A. Generic Drug Entry Into the Marketplace 4

 B. Hatch-Waxman Act 6

III. POTENTIAL COMPETITIVE IMPACT OF THE PROPOSED SETTLEMENT 10

IV. CONCLUSION 13

TABLE OF AUTHORITIES

CASES	PAGE
<i>Abbott Laboratories v. Novopharm Ltd.</i> , 104 F.3d 1305 (Fed. Cir. 1997)	9
<i>Ben Venue Laboratories, Inc. v. Novartis Pharmaceutical Corp.</i> , 10 F. Supp. 2d 446 (D.N.J. 1998)	7, 9, 10
<i>Bristol-Myers Squibb Co. v. Ben Venue Laboratories</i> , 90 F. Supp. 2d 522 (D.N.J. 2000)	6
<i>Ciba-Geigy, Ltd.</i> , 123 F.T.C. 842 (1997)	2
<i>Federal Trade Commission v. Mylan Laboratories, Inc. et al.</i> , 1999-2 Trade Cas. (CCH) ¶172,573 (D.D.C. 1999)	2
<i>Geneva Pharmaceuticals, Inc.</i> , C-3946 (May 26, 2000) (FTC consent order)	4
<i>Hoechst AG</i> , 120 F.T.C. 1010 (1995)	2
<i>Purdue Pharma. L.P. v. Boehringer Ingelheim, GmbH</i> , 2000 Lexis 6563 (S.D.N.Y. 2000)	9
<i>Rite-Hite Corp. v. Kelley Co.</i> , 56 F.3d 1538 (Fed. Cir. 1995)	8
<i>Roche Holding Ltd.</i> , C-3809 (February 25, 1998) (FTC consent order)	2
 FEDERAL STATUTES	
Federal Trade Commission Act	
15 U.S.C. § 45	1
Food and Drug Administration	
21 U.S.C. § 355(a)	6
21 U.S.C. § 355(b)(1)	7

21 U.S.C. § 355(c)(2)	10
21 U.S.C. § 355(j)(5)(B)(iv)	3
Patent	
35 U.S.C. § 271(e)(1)	8

REGULATIONS

21 C.F.R. § 314.53(b)	7, 10
21 C.F.R. § 314.53(f)	10
21 C.F.R. § 314.94	8

MISCELLANEOUS

Congressional Budget Office, <i>How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry</i> (July 1998)	5
David A. Balto & James Mongoven, Antitrust Enforcement in Pharmaceutical Industry Mergers, <i>54 Food & Drug Law Journal</i> , 255 (1999)	2
Elizabeth Dickinson, "FDA's Role in Making Exclusivity Determinations," <i>54 Food & Drug L.J.</i> , 195, 196 (1999) ...	10